Drug Profile
Research programme: enzyme precursors - Propanc Biopharma
Latest Information Update: 05 Aug 2022
Price :
$50
*
At a glance
- Originator Propanc Health Group Corporation
- Developer Propanc Biopharma; University of Granda; University of Jaen
- Class Antineoplastics; Enzyme precursors; Serine endopeptidases
- Mechanism of Action PAR-2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
- No development reported Colorectal cancer; Ovarian cancer; Pancreatic cancer
Most Recent Events
- 03 Aug 2022 Propanc Biopharma enters into a joint research collaboration agreement with the University of Jaen and University of Granda to evaluate effects of proenzyme therapy against the tumor microenvironment
- 01 Jul 2022 Preclinical trials in Solid tumours in Australia (Parenteral) before July 2022
- 28 Jun 2021 No recent reports of development identified for preclinical development in Colorectal-cancer in Australia (IV, Injection)